CA2309372A1 - Utilisation des anticorps contre la proteine nephritique dans la reduction du chimiotactisme induit pas les astrocytes infectes par retrovirus - Google Patents

Utilisation des anticorps contre la proteine nephritique dans la reduction du chimiotactisme induit pas les astrocytes infectes par retrovirus Download PDF

Info

Publication number: CA2309372A1
Authority: CA; Canada
Prior art keywords: antibodies; nef protein; nef; hiv; protein
Prior art date: 1999-09-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2309372

Other languages

English (en)

Inventor

Uwe Koedel

Birgit Kohleisen

Bernd Sporer

Fritz Lahrtz

Vladimir Ovod

Adriano Fontana

Volker Erfle

Hans-Walter Pfister

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH

Original Assignee

Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-23

Filing date

2000-06-14

Publication date

2001-03-23

2000-06-14 Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH

2001-03-23 Publication of CA2309372A1 publication Critical patent/CA2309372A1/fr

Status Abandoned legal-status Critical Current

Links

101710192141 Protein Nef Proteins 0.000 title claims abstract description 59
210000001130 astrocyte Anatomy 0.000 title claims abstract description 29
230000035605 chemotaxis Effects 0.000 title claims abstract description 20
230000003247 decreasing effect Effects 0.000 title claims abstract description 13
150000007523 nucleic acids Chemical group 0.000 claims abstract description 18
208000014644 Brain disease Diseases 0.000 claims abstract description 17
208000032274 Encephalopathy Diseases 0.000 claims abstract description 17
210000004027 cell Anatomy 0.000 claims description 46
108090000623 proteins and genes Proteins 0.000 claims description 24
108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims description 17
239000013598 vector Substances 0.000 claims description 15
102000004169 proteins and genes Human genes 0.000 claims description 13
241001430294 unidentified retrovirus Species 0.000 claims description 13
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 11
230000002163 immunogen Effects 0.000 claims description 9
208000031886 HIV Infections Diseases 0.000 claims description 8
238000001415 gene therapy Methods 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 5
230000001580 bacterial effect Effects 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
239000000243 solution Substances 0.000 claims description 4
101900170934 Simian immunodeficiency virus Protein Nef Proteins 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 3
125000000539 amino acid group Chemical group 0.000 claims description 3
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
239000004606 Fillers/Extenders Substances 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
125000000129 anionic group Chemical group 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000000872 buffer Substances 0.000 claims description 2
125000002091 cationic group Chemical group 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
239000003978 infusion fluid Substances 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
150000002632 lipids Chemical class 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
239000000314 lubricant Substances 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
239000003161 ribonuclease inhibitor Substances 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000003381 stabilizer Substances 0.000 claims description 2
239000000277 virosome Substances 0.000 claims description 2
238000001890 transfection Methods 0.000 claims 1
241000700605 Viruses Species 0.000 description 18
208000030507 AIDS Diseases 0.000 description 17
241000725303 Human immunodeficiency virus Species 0.000 description 17
210000000265 leukocyte Anatomy 0.000 description 16
210000001175 cerebrospinal fluid Anatomy 0.000 description 15
108700004028 nef Genes Proteins 0.000 description 14
230000000694 effects Effects 0.000 description 13
208000015181 infectious disease Diseases 0.000 description 13
238000001727 in vivo Methods 0.000 description 12
101150023385 nef gene Proteins 0.000 description 12
241000700159 Rattus Species 0.000 description 11
230000003399 chemotactic effect Effects 0.000 description 11
238000000034 method Methods 0.000 description 11
210000003169 central nervous system Anatomy 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
210000000224 granular leucocyte Anatomy 0.000 description 10
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
238000000338 in vitro Methods 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
210000001744 T-lymphocyte Anatomy 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000011161 development Methods 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
238000012360 testing method Methods 0.000 description 6
101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
102000000018 Chemokine CCL2 Human genes 0.000 description 5
102000004889 Interleukin-6 Human genes 0.000 description 5
108090001005 Interleukin-6 Proteins 0.000 description 5
102000003896 Myeloperoxidases Human genes 0.000 description 5
108090000235 Myeloperoxidases Proteins 0.000 description 5
102100040247 Tumor necrosis factor Human genes 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
230000006870 function Effects 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
229940100601 interleukin-6 Drugs 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
239000013642 negative control Substances 0.000 description 5
210000002569 neuron Anatomy 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
241000713311 Simian immunodeficiency virus Species 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000029812 viral genome replication Effects 0.000 description 4
206010003571 Astrocytoma Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
208000029462 Immunodeficiency disease Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
230000007813 immunodeficiency Effects 0.000 description 3
239000003550 marker Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
210000000274 microglia Anatomy 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
210000002433 mononuclear leukocyte Anatomy 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
238000011552 rat model Methods 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
210000004248 oligodendroglia Anatomy 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical compound CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
208000032420 Latent Infection Diseases 0.000 description 1
241000283986 Lepus Species 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000282579 Pan Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
101800000874 Small capsid protein Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000011225 antiretroviral therapy Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000001043 capillary endothelial cell Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004154 complement system Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000035800 maturation Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
108700004030 rev Genes Proteins 0.000 description 1
101150098213 rev gene Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000002795 scorpion venom Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
108700004027 tat Genes Proteins 0.000 description 1
101150098170 tat gene Proteins 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000007482 viral spreading Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

CA 2309372 1999-09-23 2000-06-14 Utilisation des anticorps contre la proteine nephritique dans la reduction du chimiotactisme induit pas les astrocytes infectes par retrovirus Abandoned CA2309372A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40441099A	1999-09-23	1999-09-23
US09/404,410		1999-09-23

Publications (1)

Publication Number	Publication Date
CA2309372A1 true CA2309372A1 (fr)	2001-03-23

Family

ID=23599492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2309372 Abandoned CA2309372A1 (fr)	1999-09-23	2000-06-14	Utilisation des anticorps contre la proteine nephritique dans la reduction du chimiotactisme induit pas les astrocytes infectes par retrovirus

Country Status (2)

Country	Link
JP (1)	JP2001247476A (fr)
CA (1)	CA2309372A1 (fr)

2000
- 2000-01-19 JP JP2000010961A patent/JP2001247476A/ja active Pending
- 2000-06-14 CA CA 2309372 patent/CA2309372A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
JP2001247476A (ja)	2001-09-11

Publication	Publication Date	Title
Ma et al.	2004	Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection
JP4434478B2 (ja)	2010-03-17	リエンジニアリングされた外被を有するラブドウイルス
Schwartz et al.	1993	Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef
EA029198B1 (ru)	2018-02-28	Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа
JPH02501192A (ja)	1990-04-26	可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
Chao et al.	1989	A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion
JP2003506410A (ja)	2003-02-18	ウィルス感染性を阻止するペプチドおよびその使用方法
Jafari et al.	2014	Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release
Fujinaga et al.	1995	Extracellular Nef protein regulates productive HIV-1 infection from latency
JP2004522401A (ja)	2004-07-29	ワクチンおよび治療薬としてのｃｄ４非依存性のｈｉｖエンベロープタンパク質
Miller et al.	1997	Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity
Foster et al.	2001	Genetic and functional diversity of human immunodeficiency virus type 1 subtype B Nef primary isolates
Perrin et al.	1998	Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein
Agadjanyan et al.	1994	Identification of an 80-kilodalton membrane glycoprotein important for human T-cell leukemia virus type I and type II syncytium formation and infection
BALL et al.	1997	Basolateral sorting of the HIV type 2 and SIV envelope glycoproteins in polarized epithelial cells: role of the cytoplasmic domain
Pincus et al.	1990	Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.
EP0917585B1 (fr)	2007-04-11	VECTEURS DE DéLIVRANCE PERMETTANT D'INHIBER LA CROISSANCE VIRALE OU TUMORALE
CA2309372A1 (fr)	2001-03-23	Utilisation des anticorps contre la proteine nephritique dans la reduction du chimiotactisme induit pas les astrocytes infectes par retrovirus
US5962635A (en)	1999-10-05	Therapeutic compounds
US5567805A (en)	1996-10-22	The cellular receptor for the CS3 peptide of human immunodeficiency virus
US20100135989A1 (en)	2010-06-03	Anti-hiv agents
WO1998003669A9 (fr)	1998-04-23	Vecteurs d'administration d'inhibiteurs de cellules virales et oncogenes
Hemming et al.	1989	Cystein 402 of HIV gp120 is essential for CD4-binding and resistance of gp120 to intracellular degradation
Sawai et al.	1997	Nef and the Nef-associated kinase
US6953687B1 (en)	2005-10-11	Vectors for delivering viral and oncogenic inhibitors

Legal Events

Date	Code	Title	Description
2004-06-14	FZDE	Dead